JP2014077003A5 - - Google Patents

Download PDF

Info

Publication number
JP2014077003A5
JP2014077003A5 JP2013257143A JP2013257143A JP2014077003A5 JP 2014077003 A5 JP2014077003 A5 JP 2014077003A5 JP 2013257143 A JP2013257143 A JP 2013257143A JP 2013257143 A JP2013257143 A JP 2013257143A JP 2014077003 A5 JP2014077003 A5 JP 2014077003A5
Authority
JP
Japan
Prior art keywords
ischemia
pharmaceutical composition
final dose
reperfusion injury
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013257143A
Other languages
English (en)
Japanese (ja)
Other versions
JP5767307B2 (ja
JP2014077003A (ja
Filing date
Publication date
Priority claimed from US12/466,170 external-priority patent/US7928067B2/en
Application filed filed Critical
Publication of JP2014077003A publication Critical patent/JP2014077003A/ja
Publication of JP2014077003A5 publication Critical patent/JP2014077003A5/ja
Application granted granted Critical
Publication of JP5767307B2 publication Critical patent/JP5767307B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013257143A 2009-05-14 2013-12-12 虚血および虚血・再灌流障害を治療するための組成物および方法 Active JP5767307B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/466,170 2009-05-14
US12/466,170 US7928067B2 (en) 2009-05-14 2009-05-14 Compositions and methods for treating ischemia and ischemia-reperfusion injury

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2012511009A Division JP5570590B2 (ja) 2009-05-14 2010-05-13 虚血および虚血・再灌流障害を治療するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2014077003A JP2014077003A (ja) 2014-05-01
JP2014077003A5 true JP2014077003A5 (OSRAM) 2014-07-10
JP5767307B2 JP5767307B2 (ja) 2015-08-19

Family

ID=42244916

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012511009A Active JP5570590B2 (ja) 2009-05-14 2010-05-13 虚血および虚血・再灌流障害を治療するための組成物および方法
JP2013257143A Active JP5767307B2 (ja) 2009-05-14 2013-12-12 虚血および虚血・再灌流障害を治療するための組成物および方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2012511009A Active JP5570590B2 (ja) 2009-05-14 2010-05-13 虚血および虚血・再灌流障害を治療するための組成物および方法

Country Status (16)

Country Link
US (5) US7928067B2 (OSRAM)
EP (1) EP2429519B1 (OSRAM)
JP (2) JP5570590B2 (OSRAM)
KR (1) KR101636395B1 (OSRAM)
CN (1) CN102802622B (OSRAM)
AU (1) AU2010249001B2 (OSRAM)
BR (1) BRPI1012182A2 (OSRAM)
CA (1) CA2761798C (OSRAM)
DK (1) DK2429519T3 (OSRAM)
ES (1) ES2470673T3 (OSRAM)
IL (2) IL216349A (OSRAM)
MX (2) MX347460B (OSRAM)
NZ (1) NZ596364A (OSRAM)
PL (1) PL2429519T3 (OSRAM)
SG (1) SG176062A1 (OSRAM)
WO (1) WO2010132657A1 (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8541396B2 (en) 2009-04-24 2013-09-24 National University Of Singapore Morpholin-4-ium 4 methoxyphenyl (morpholino) phosphinodithioate (GYY4137) as a novel vasodilator agent
US7928067B2 (en) 2009-05-14 2011-04-19 Ischemix Llc Compositions and methods for treating ischemia and ischemia-reperfusion injury
WO2012067947A1 (en) * 2010-11-18 2012-05-24 Ischemix Llc Lipoyl compounds and their use for treating ischemic injury
EP2540292A1 (en) * 2011-06-28 2013-01-02 Nestec S.A. DHA and EPA in the reduction of oxidative stress
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
CN115927242A (zh) 2012-05-11 2023-04-07 珍白斯凯尔有限公司 具有抗炎活性的肽及其在制备抗炎组合物中的应用
CN104507489B (zh) 2012-05-11 2016-07-13 杰姆维克斯&凯尔有限公司 用于预防和治疗类风湿性关节炎的组合物
ES2981865T3 (es) 2012-07-11 2024-10-10 Gemvax & Kael Co Ltd Conjugado que comprende un péptido de penetración celular y composiciones que comprenden el mismo
ES2716870T3 (es) 2013-04-19 2019-06-17 Gemvax & Kael Co Ltd Composición para el tratamiento y prevención de lesión isquémica
CN105535931A (zh) 2013-06-07 2016-05-04 凯尔杰姆维克斯有限公司 在癌症免疫疗法中有用的生物标记
EP3011967B1 (en) 2013-06-21 2020-06-17 Gemvax & Kael Co., Ltd. Hormone secretion regulator, composition containing same, and method for controlling hormone secretion using same
JP6382972B2 (ja) 2013-10-23 2018-08-29 ジェムバックス アンド カエル カンパニー，リミティド 前立腺肥大治療用及びその予防用の組成物
JP6553605B2 (ja) 2013-11-22 2019-07-31 ジェムバックス アンド カエル カンパニー，リミティド 血管新生抑制活性を有するペプチド、及びそれを含む組成物
JP6367950B2 (ja) 2013-12-17 2018-08-01 ジェムバックス アンド カエル カンパニー，リミティド 前立腺癌治療用組成物
CN106456697B (zh) 2014-04-11 2019-12-17 珍白斯凯尔有限公司 具有纤维化抑制活性的肽和含有其的组合物
KR102232320B1 (ko) 2014-04-30 2021-03-26 주식회사 젬백스앤카엘 장기, 조직 또는 세포 이식용 조성물, 키트 및 이식 방법
WO2015174948A1 (en) 2014-05-14 2015-11-19 Ischemix, LLC Formulations comprising lipoyl compounds
CN104095835A (zh) * 2014-06-20 2014-10-15 广州军区广州总医院 对羟基苄叉丙酮在制备预防和/或治疗肝缺血/再灌注损伤药物中的应用
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
CN107405380B (zh) 2015-02-27 2021-04-20 珍白斯凯尔有限公司 用于预防听觉损伤的肽及其包含该肽的组合物
EP3318265B1 (en) 2015-07-02 2021-08-18 Gemvax & Kael Co., Ltd. Peptide having anti-viral effect and composition containing same
ES2949697T3 (es) 2016-04-07 2023-10-02 Gemvax & Kael Co Ltd Péptido que tiene efectos de aumento de la actividad telomerasa y de extensión de los telómeros, y composición que contienen el mismo
CN106083800A (zh) * 2016-06-13 2016-11-09 崔坤峰 氯普噻吨的药物组合物及对脑缺血再灌注损伤的保护作用
DK3522880T3 (en) * 2016-10-05 2021-01-18 Mitokyne Inc Methods of treating acute kidney injury
US10744115B2 (en) 2017-04-25 2020-08-18 Ischemix Llc Compositions and methods for treating traumatic brain injury
KR102139678B1 (ko) 2017-11-24 2020-07-31 전북대학교 산학협력단 N-아세틸 또는 n-아실 아미노산을 포함하는 아토피 또는 가려움증 치료용 조성물
KR102112949B1 (ko) 2019-02-12 2020-05-19 남현규 복합 효모 발효로 불용 단백질을 가용화하여 화장품원료를 추출하는 화장품원료 제조방법

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1047991B (de) 1957-11-20 1958-12-31 Nordmark Werke Gmbh Verfahren zur Herstellung chemisch stabiler, untoxischer, steriler Injektionsloesungen von Thioctsaeure
US3875207A (en) * 1967-01-25 1975-04-01 Ciba Geigy Corp Process for the temporary protection of amino groups in peptide syntheses
CA1219824A (en) 1981-04-17 1987-03-31 David C. Ward Modified nucleotides and methods of preparing and using same
US5288706A (en) * 1987-12-25 1994-02-22 Mitsui Toatsu Chemicals, Incorporated Medicament for prevention and remedy of diseases of the pancreas and others
FR2653334B1 (fr) 1989-10-19 1991-12-20 Erphar Ste Civile Preparation cosmetique de bronzage.
EP0812590A3 (de) 1989-11-09 1999-06-09 ASTA Medica Aktiengesellschaft Verwendung von R-Alpha-Liponsäure zur Zytoprotektion
DE4000397A1 (de) 1990-01-09 1991-07-11 Hoechst Ag Lipidselektive antioxidantien sowie deren herstellung und verwendung
EP0639989B1 (en) 1992-04-24 2001-06-27 Biocompatibles Limited Method of reducing microorganism adhesion
DE4235912C2 (de) 1992-10-23 2002-12-05 Viatris Gmbh Verfahren zur Herstellung kristalliner Thioctsäure und deren Verwendung
DE4433764A1 (de) 1994-09-22 1996-03-28 Asta Medica Ag Darreichungsformen enthaltend alpha-Liponsäure, feste Salze von R-Thioctsäure mit verbesserter Freisetzung und Bioverfügbarkeit
EP0838472A4 (en) * 1995-06-21 2000-02-02 Asahi Chemical Ind LOW DENSITY LIPOPROTEIN BINDING PEPTIDES
JPH0990542A (ja) 1995-09-28 1997-04-04 Konica Corp ハロゲン化銀写真感光材料
FR2741075B1 (fr) 1995-11-15 1998-01-30 Rech De Pathologie Appliquee S Conjugues peptidiques, leur utilisation a titre de medicament et compositions les contenant
IL123887A0 (en) 1997-04-02 1998-10-30 Sankyo Co Dithiolan derivatives their use and pharmaceutical compositions containing the same
JPH117099A (ja) 1997-06-13 1999-01-12 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
US6090842A (en) 1998-03-10 2000-07-18 The Regents Of The University Of California Lipoic acid analogs
DE19834608A1 (de) 1998-07-31 2000-02-03 Basf Ag Kristallmodifikation der Liponsäure
JP2000169371A (ja) 1998-10-02 2000-06-20 Sankyo Co Ltd ジチオラン誘導体を含有する医薬
EP1133317A1 (de) 1998-11-26 2001-09-19 Pentapharm AG Transportsystemkonjugate
WO2001009118A2 (en) 1999-07-29 2001-02-08 Patrick T Prendergast Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
US6890896B1 (en) 1999-11-18 2005-05-10 Ceremedix, Inc. Compositions and methods for counteracting effects of reactive oxygen species and free radicals
JP2003518477A (ja) * 1999-11-18 2003-06-10 セレメディックス，インク． 反応性酸素種およびフリーラジカルの効力を中和するための組成物および方法
US6664287B2 (en) 2000-03-15 2003-12-16 Bethesda Pharmaceuticals, Inc. Antioxidants
JP2002189271A (ja) 2000-12-21 2002-07-05 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料およびその処理方法
US7700080B2 (en) 2001-03-19 2010-04-20 Senju Pharmaceutical Co., Ltd. Method of suppressing melanin production by metal chelates of lipoyl amino acid derivatives
EP1521735A2 (en) 2001-05-25 2005-04-13 Ceremedix, Inc Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals
JP4259813B2 (ja) 2001-05-29 2009-04-30 千寿製薬株式会社 α−リポイルアミノ酸の安定化法および安定化されたα−リポイルアミノ酸を含有する水性液剤
DE10163836A1 (de) 2001-12-22 2003-07-10 Friz Biochem Gmbh Multifunktionales Reagenz zur Synthese von thiolmodifizierten Oligomeren
WO2003055853A1 (en) 2001-12-26 2003-07-10 Nippon Soda Co., Ltd. Electron-accepting compounds capable of forming self-assembled monolayers
AUPS065102A0 (en) 2002-02-20 2002-03-14 Unisearch Limited Fluorous acetalation
WO2003072052A2 (en) 2002-02-22 2003-09-04 Albany College Of Pharmacy Methods and compounds useful in inhibiting oxidative and/or free radical damage and in the treatment and prevention of disease
JP2003286168A (ja) 2002-03-28 2003-10-07 Senju Pharmaceut Co Ltd α−リポイルアミノ酸を含有する皮膚外用剤
JP4376540B2 (ja) 2002-05-31 2009-12-02 アイバイツ株式会社 金属表面修飾剤および新規含硫黄化合物
US7030154B2 (en) 2002-06-07 2006-04-18 Juvenon, Inc. Stability of lipoic acid
TWI331034B (en) 2002-07-08 2010-10-01 Piramal Life Sciences Ltd Inhibitors of cyclin-dependent kinases and their use
EP1454627A1 (en) 2003-03-06 2004-09-08 MyoContract Ltd. Alpha-Keto carbonyl calpain inhibitors
US20040204340A1 (en) * 2003-04-11 2004-10-14 Guilford Pharmaceuticals, Inc. Polyprolyl inhibitors of cyclophilin
US7202270B2 (en) 2003-06-20 2007-04-10 Sami Labs Limited Convenient stable non-hygroscopic crystalline solid forms of racemic and chiral LA-plus salts: process for their manufacture and uses
US8088935B2 (en) 2003-12-23 2012-01-03 Ironwood Pharmaceuticals, Inc. Compounds and methods for the treatment of asthma
US8765384B2 (en) 2004-02-18 2014-07-01 Japan Science And Technology Agency Carbohydrate-ligand conjugates and their application for the analysis of carbohydrate-protein interaction
JP2006022066A (ja) 2004-07-09 2006-01-26 Shiseido Co Ltd 重合抑制剤および即時型黒化防止用皮膚外用剤
WO2006101909A2 (en) 2005-03-16 2006-09-28 Ischemix, Inc. Combination therapy for treating or preventing diseases
WO2006101910A2 (en) 2005-03-16 2006-09-28 Ischemix, Inc. Peptide compounds and methods of using peptide compounds to treat conditions affecting the cardiac, pulmonary, and nervous systems
JP2008174453A (ja) 2005-04-28 2008-07-31 Iwaki Kk 頭皮脱毛治療剤
EP1957093B1 (en) * 2005-08-29 2017-04-12 SHASHOUA, Victor E. Neuroprotective and neurorestorative methods and compositions
JP4951226B2 (ja) 2005-09-08 2012-06-13 立山化成株式会社 α−リポ酸アルカリ塩の製法
EP1940419A2 (en) * 2005-09-09 2008-07-09 Oregon Health and Science University Neuroprotectants
DE602006013787D1 (de) 2006-03-28 2010-06-02 Epitech Group Srl Eine Pharmazeutische Zusammensetzung zur Behandlung von Pathologien, die durch die allgemeine Immunantwort verursacht werden
US20110212954A1 (en) 2008-11-07 2011-09-01 Mario Brufani Alpha-lipoic acid derivatives and their use in drug preparation
US7928067B2 (en) 2009-05-14 2011-04-19 Ischemix Llc Compositions and methods for treating ischemia and ischemia-reperfusion injury
US8080674B2 (en) 2009-06-12 2011-12-20 Ampac Fine Chemicals Llc. Preparation of polymer-free R-(+)-α-lipoic acid magnesium salt
WO2010147957A2 (en) 2009-06-15 2010-12-23 Encore Health, Llc Dithiol compounds, derivatives, and uses therefor
PT2821405E (pt) 2009-06-15 2016-06-14 Encore Health Llc Ésteres de colina para tratar a presbiopia e a catarata
IT1397154B1 (it) 2010-01-04 2013-01-04 Ghelardini Composti ad efficacia sia analgesica che antiperalgesica.
WO2012067947A1 (en) 2010-11-18 2012-05-24 Ischemix Llc Lipoyl compounds and their use for treating ischemic injury
US20150329519A1 (en) 2014-05-14 2015-11-19 Ischemix, LLC Formulations Comprising Lipoyl Compounds
WO2015174948A1 (en) 2014-05-14 2015-11-19 Ischemix, LLC Formulations comprising lipoyl compounds

Similar Documents

Publication Publication Date Title
JP2014077003A5 (OSRAM)
US10166246B2 (en) TGR5 agonist complexes for treating diabetes and cancer
JP2016510326A5 (OSRAM)
JP2012529486A5 (OSRAM)
JP2016530280A5 (OSRAM)
JP2018076328A5 (OSRAM)
JP2019515908A5 (OSRAM)
BRPI0909625B1 (pt) Agonista seletivo do receptor s1p1 para o uso como um medicamento, uso de um agonista seletivo do receptor s1p1 e kit contendo diferentes unidades de medicação de um agonista seletivo do receptor s1p1
RU2012134510A (ru) Применение агента, обладающего модифицирующими свойствами в отношении гормонов надпочечников
JP2018534348A5 (OSRAM)
JP2015057436A5 (OSRAM)
JP2017527532A5 (OSRAM)
JP2015535243A5 (OSRAM)
JP2010270124A5 (OSRAM)
JP2013501731A5 (OSRAM)
JP2016528162A5 (OSRAM)
JP2020521797A5 (OSRAM)
JP2016515628A5 (OSRAM)
JP2015508068A5 (OSRAM)
TWI669113B (zh) 用於治療癌症之氧烯洛爾（ｏｘｐｒｅｎｏｌｏｌ）組合物
JP2014139255A5 (OSRAM)
JP2019520344A5 (OSRAM)
JP2017533220A5 (OSRAM)
JP2018531605A5 (OSRAM)
JP2019533660A5 (OSRAM)